Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacTRL nAB
- Development stage
- Preclinical
- Lead developer
- Symvivo
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Silencing → Gene Therapies, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Editing → Gene Therapies, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Addition/Replacement → Gene Therapies
- Administration
- Oral, Intravenous
01
Overview
bacTRL nAB is a preclinical gene therapy candidate developed by Symvivo for the treatment or prevention of COVID-19. It utilizes Symvivo's proprietary **bacTRL™** platform, which employs engineered *Bifidobacterium longum* (a probiotic bacterium) as a vector to deliver plasmid DNA directly to the patient's cells, typically via oral or intravenous administration. In this specific application, the plasmid is designed to encode neutralizing antibodies (nAbs) against the SARS-CoV-2 virus. Once the DNA is internalized by the host's cells, the cells' own machinery produces and secretes the therapeutic antibodies *in vivo*. This approach aims to provide a scalable and potentially long-lasting alternative to traditional monoclonal antibody infusions by turning the patient's own body into a factory for the therapeutic protein.
- Other names
- bacTRL neutralizing antibodybacTRL-nABbacTRL neutralizing antibody-Symvivo-gene therapy-DNA-encoded antibody (inferred)-oral, IV-COVID-19
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on bacTRL nAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacTRL nAB.